RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
The formulation is backed by over 80 clinical trials and 200 scientific publications
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Subscribe To Our Newsletter & Stay Updated